AI Therapeutics, Inc. Report issue

For profit Phase 2
Founded: Guilford CT United States (2013)

Organization Overview

First Clinical Trial
2020
NCT04446377
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

AI Therapeutics, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

apilimod mesylate (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease Progression (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1